There is still a plausible path for Peak to build a rare earth supply chain without any Chinese involvement. Use the funds from Shenghe for the ore concentrate to develop and build a refinery (whether in Tanzania or in the UK is irrelevant to the broader point). Once the refinery is built, the need for Shenghe as a source of funds will be gone: Peak will be able to go directly to end users of rare earths.
Remember that Shenghe has only 19.9% of the company; that the MoU is non-binding (though likely to turn to a binding contract in some form); and that there is nothing to say that Peak is obliged to keep supplying after the term expires.
Concerning from a geopolitical situation? Sure. I've never said otherwise. But from the company's perspective - what reasonable alternative is there? I've asked that question a few times, and I'm yet to get an answer from you - or anybody else for that matter - that addresses that key question. Deal with the hand that you've got, not the hand you wish you were dealt.
- Forums
- ASX - By Stock
- Ann: Peak and Shenghe Sign Offtake and Strategic Co-operation MOU
There is still a plausible path for Peak to build a rare earth...
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PEK (ASX) to my watchlist
|
|||||
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $53.28M |
Open | High | Low | Value | Volume |
20.0¢ | 20.0¢ | 20.0¢ | $2.284K | 11.42K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 59520 | 19.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.5¢ | 20130 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 59520 | 0.195 |
3 | 162631 | 0.190 |
2 | 105000 | 0.185 |
2 | 39000 | 0.180 |
7 | 26937 | 0.175 |
Price($) | Vol. | No. |
---|---|---|
0.205 | 20130 | 2 |
0.210 | 46911 | 2 |
0.215 | 37928 | 1 |
0.220 | 60000 | 2 |
0.225 | 66158 | 3 |
Last trade - 11.35am 14/08/2024 (20 minute delay) ? |
Featured News
PEK (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online